The Experts below are selected from a list of 252 Experts worldwide ranked by ideXlab platform
Jg Kadar - One of the best experts on this subject based on the ideXlab platform.
-
Imprecision of counting CFU-GM colonies and CD34-expressing cells
Bone Marrow Transplantation, 1997Co-Authors: Stefan Serke, L Arseniev, Michael J. Watts, G Fritsch, J. Inglés-esteve, Hans Erik Johnsen, Dc Linch, Jose A. Cancelas, O. Meyer, Jg KadarAbstract:Summary: introduced relevant changes in the management of the harvest of haemopoietic cells by Cytapheresis. 3 It is well-recognized that neither CFU-GM nor the total
-
Imprecision of counting CFU-GM colonies and CD34-expressing cells
Bone Marrow Transplantation, 1997Co-Authors: Stefan Serke, L Arseniev, G Fritsch, J. Inglés-esteve, Dc Linch, Jose A. Cancelas, O. Meyer, M Watts, He Johnsen, Jg KadarAbstract:Determinations of committed haemopoietic progenitor cells, namely CFU-GM (colony-forming unit–granulocyte/macrophage) and of CD34-expressing haemopoietic cells as assessed by multiparameter flow cytometry are routine diagnostic tools in haemopoietic cell therapy. Generally, the tests are used to optimise the timing and management of Cytapheresis and to assess the engraftment potential of the harvested cells. Both measurements, however, are at best surrogate markers, as an adequate routine test which effectively assesses the short- and long-term repopulating haemopoietic cell is not available. Nonetheless, cell threshold doses have been established. Above these thresholds rapid engraftment is almost invariable but below these thresholds the outcome is variable. In this study we have focussed on the imprecision in counting haemopoietic cells, as assessed as CFU-GM and as CD34-expressing cells. The data on both tests have been analysed from six European institutions. The coefficient of variation in CFU-GM colony counting was about 30%, whereas the coefficient of variation in flow cytometric counting of CD34-expressing cells was about 10%. These data suggest that the technical imprecision in enumerating progenitor cells, particularly CFU-GM, at low levels, might make a major contribution to the clinical variability observed after transplantation of sub-threshold progenitor cell dose.
Stefan Serke - One of the best experts on this subject based on the ideXlab platform.
-
Imprecision of counting CFU-GM colonies and CD34-expressing cells
Bone Marrow Transplantation, 1997Co-Authors: Stefan Serke, L Arseniev, Michael J. Watts, G Fritsch, J. Inglés-esteve, Hans Erik Johnsen, Dc Linch, Jose A. Cancelas, O. Meyer, Jg KadarAbstract:Summary: introduced relevant changes in the management of the harvest of haemopoietic cells by Cytapheresis. 3 It is well-recognized that neither CFU-GM nor the total
-
Imprecision of counting CFU-GM colonies and CD34-expressing cells
Bone Marrow Transplantation, 1997Co-Authors: Stefan Serke, L Arseniev, G Fritsch, J. Inglés-esteve, Dc Linch, Jose A. Cancelas, O. Meyer, M Watts, He Johnsen, Jg KadarAbstract:Determinations of committed haemopoietic progenitor cells, namely CFU-GM (colony-forming unit–granulocyte/macrophage) and of CD34-expressing haemopoietic cells as assessed by multiparameter flow cytometry are routine diagnostic tools in haemopoietic cell therapy. Generally, the tests are used to optimise the timing and management of Cytapheresis and to assess the engraftment potential of the harvested cells. Both measurements, however, are at best surrogate markers, as an adequate routine test which effectively assesses the short- and long-term repopulating haemopoietic cell is not available. Nonetheless, cell threshold doses have been established. Above these thresholds rapid engraftment is almost invariable but below these thresholds the outcome is variable. In this study we have focussed on the imprecision in counting haemopoietic cells, as assessed as CFU-GM and as CD34-expressing cells. The data on both tests have been analysed from six European institutions. The coefficient of variation in CFU-GM colony counting was about 30%, whereas the coefficient of variation in flow cytometric counting of CD34-expressing cells was about 10%. These data suggest that the technical imprecision in enumerating progenitor cells, particularly CFU-GM, at low levels, might make a major contribution to the clinical variability observed after transplantation of sub-threshold progenitor cell dose.
-
In-vitro clonogenicity of mobilized peripheral blood CD34-expressing cells: inverse correlation to both relative and absolute numbers of CD34-expressing cells.
British Journal of Haematology, 1996Co-Authors: Stefan Serke, Michael J. Watts, Lenen Meldgaard Knudsen, Carla Kreissig, Ulrike Schneider, N. Schwella, David C. Linch, Hans Erik JohnsenAbstract:The determination of CD34-expressing cells by multiparameter flow cytometry is now widely used to estimate the reconstitution potential of cells harvested by Cytapheresis for peripheral blood stem cell and progenitor cell transplantation. There is a correlation between the number of CD34-expressing cells collected and committed progenitor cells (CFU-GM and BFU-E) capable of forming colonies in vitro, but there is considerable variation in the proportion of CD34-expressing cells capable of clonogenic growth. The data in this study of 782 Cytapheresis samples indicates that there is a negative correlation between the clonogenicity of the CD34-expressing cells and the absolute number or the proportion of CD34-expressing cells within the harvest. In 116 samples the proportion of CD34-expressing cells co-expressing the CD45-RA-antigen (a subset of CD34-expressing cells which includes virtually all clonogenic cells in terms of CFU-GM) was determined, but this did not help to identify the clonogenicity of a given sample. These findings may have clinical relevance, particularly when mobilization is judged to be relatively poor or when a good harvest is to be divided for multiple high-dose procedures.
Midori Hasegawa - One of the best experts on this subject based on the ideXlab platform.
-
effects of Cytapheresis on tumor necrosis factor receptor and on expression of cd63 in myeloperoxidase antineutrophil cytoplasmic autoantibody associated vasculitis
Therapeutic Apheresis and Dialysis, 2007Co-Authors: Midori Hasegawa, Kazutaka Murakami, Makoto Tomita, Kunihiro Nabeshima, Atsushi Ohashi, Nao Kabutan, Masao Kato, Chikako Nishii, Shigeru Nakai, Yoshiyuki HikiAbstract:To evaluate the therapeutic potential of Cytapheresis in myeloperoxidase-antineutrophil cytoplasmic autoantibody (MPO-ANCA)-associated vasculitis, plasma levels of soluble tumor necrosis factor receptors (sTNFR1, sTNFR2) and the expression of TNFR1, TNFR2, and CD63 on granulocytes were measured. The levels of sTNFR1 and sTNFR2, and the expression of TNFR1 and TNFR2 were significantly higher in MPO-ANCA-associated vasculitis patients than in normal controls. The levels of sTNFR1 and sTNFR2 increased significantly after Cytapheresis (P < 0.001). The expression of TNFR1 showed a tendency to decrease after Cytapheresis (P = 0.0535). The expression of CD63 decreased significantly after Cytapheresis (P < 0.05). Because sTNFR1 and sTNFR2 act as TNF-antagonists, the increases of sTNFR1 and sTNFR2 after Cytapheresis might contribute to inhibit the action of TNF-alpha. The decreased expression of TNFR1, which mediates the signal for polymorphonuclear cell respiratory burst, might also contribute to the reduction of inflammation. From these results, the inhibition of TNF action and removal of degranulated granulocytes appear to be related to the mechanism whereby Cytapheresis can exert a beneficial and therapeutic function in the treatment of MPO-ANCA-associated vasculitis.
-
Effects of Cytapheresis on Tumor Necrosis Factor Receptor and on Expression of CD63 in Myeloperoxidase–Antineutrophil Cytoplasmic Autoantibody-associated Vasculitis
Therapeutic Apheresis and Dialysis, 2007Co-Authors: Midori Hasegawa, Kazutaka Murakami, Makoto Tomita, Kunihiro Nabeshima, Atsushi Ohashi, Nao Kabutan, Masao Kato, Chikako Nishii, Shigeru Nakai, Yoshiyuki HikiAbstract:To evaluate the therapeutic potential of Cytapheresis in myeloperoxidase-antineutrophil cytoplasmic autoantibody (MPO-ANCA)-associated vasculitis, plasma levels of soluble tumor necrosis factor receptors (sTNFR1, sTNFR2) and the expression of TNFR1, TNFR2, and CD63 on granulocytes were measured. The levels of sTNFR1 and sTNFR2, and the expression of TNFR1 and TNFR2 were significantly higher in MPO-ANCA-associated vasculitis patients than in normal controls. The levels of sTNFR1 and sTNFR2 increased significantly after Cytapheresis (P < 0.001). The expression of TNFR1 showed a tendency to decrease after Cytapheresis (P = 0.0535). The expression of CD63 decreased significantly after Cytapheresis (P < 0.05). Because sTNFR1 and sTNFR2 act as TNF-antagonists, the increases of sTNFR1 and sTNFR2 after Cytapheresis might contribute to inhibit the action of TNF-alpha. The decreased expression of TNFR1, which mediates the signal for polymorphonuclear cell respiratory burst, might also contribute to the reduction of inflammation. From these results, the inhibition of TNF action and removal of degranulated granulocytes appear to be related to the mechanism whereby Cytapheresis can exert a beneficial and therapeutic function in the treatment of MPO-ANCA-associated vasculitis.
-
Cytapheresis for the treatment of myeloperoxidase antineutrophil cytoplasmic autoantibody associated vasculitis a pilot study of 21 patients
Therapeutic Apheresis and Dialysis, 2006Co-Authors: Midori Hasegawa, Kazutaka Murakami, Makoto Tomita, Kunihiro Nabeshima, Atsushi Ohashi, Nao Kabutan, Saori Hiramatsu, Masao Kato, Yoshiyuki Hiki, Satoshi SugiyamaAbstract:Abstract: Twenty-one patients with myeloperoxidase-antineutrophil cytoplasmic autoantibody (MPO-ANCA)-associated vasculitis were treated using Cytapheresis. Of these, 17 were treated for glomerulonephritis and four were treated for pulmonary hemorrhage. The overall survival rate was 85.7% with a follow-up duration of 24.0 ± 13.8 months. In the 17 patients with MPO-ANCA-associated glomerulonephritis, pretreatment creatinine was 3.2 ± 1.6 mg/dL, and renal function recovered in 76.5%. Pulmonary hemorrhage was ameliorated in all four patients. Abdominal pain occurred in three of the 21 patients but symptoms resolved soon after the Cytapheresis procedure was completed. No other adverse effects occurred during Cytapheresis. From these results, Cytapheresis can be considered a safe and effective treatment for MPO-ANCA-associated vasculitis. As for the mechanism of its action, soluble tumor necrosis factor receptor 1 (sTNFR), sTNFR2 and interleukin 1 receptor antagonist were elevated soon after Cytapheresis and those levels 2 h after the Cytapheresis procedure were higher than before the procedure in some cases. These elevations might be related to the efficacy of Cytapheresis.
-
treatment with Cytapheresis for antineutrophil cytoplasmic antibody associated renal vasculitis and its effect on anti inflammatory factors
Therapeutic Apheresis and Dialysis, 2005Co-Authors: Midori Hasegawa, Asako Watanabe, Hiroki Takahashi, Kazuo Takahashi, Masami Kasugai, Nahoko Kawamura, Hiroko Kushimoto, Kazutaka Murakami, Makoto Tomita, Kunihiro NabeshimaAbstract:: To evaluate the efficacy of Cytapheresis for the treatment of rapidly progressive glomerulonephritis (RPGN) caused by myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA)-associated vasculitis, the renal prognosis and the mortality rate at 1 year after treatment were compared between a Cytapheresis Group and a Steroid Pulse Group. The Cytapheresis Group included 10 patients who were treated with Cytapheresis and oral corticosteroids. Five had granuloCytapheresis with the Adacolumn (Japan Immuno Research Laboratories Co. Ltd, Takasaki, Japan) and the remaining five had leukoCytapheresis with the leukocyte removal filter, Cellsorba (Asahi Medical Co. Ltd, Tokyo, Japan). The Steroid Pulse Group was comprised of 12 patients who were treated with methylprednisolone pulse therapy and oral corticosteroids. In the Cytapheresis Group, renal function recovered in 70% of the patients and the mortality rate was 10%. In the Steroid Pulse Group, renal function recovered in 66.7% and the mortality rate was 33.3%, with infection as the cause of death. Total doses of corticosteroids converted to prednisolone dose during a 1 month period, ranged from 280 mg to 1226 mg in the Cytapheresis Group. On the other hand, these dosages ranged from 2375 mg to 8380 mg in the Steroid Pulse Group. These results indicated that the mortality rate by infection could be reduced by adding Cytapheresis therapy. Concerning the mechanism of Cytapheresis, anti-inflammatory factors such as soluble tumor necrosis factor receptor, and interleukin-10 reduced after Cytapheresis. These changes might be responsible for the efficacy of Cytapheresis. In conclusion, Cytapheresis is thought to be one of the effective treatments for RPGN caused by MPO-ANCA-associated vasculitis, reducing the levels of anti-inflammatory factors.
-
Treatment With Cytapheresis for Antineutrophil Cytoplasmic Antibody‐associated Renal Vasculitis and Its Effect on Anti‐inflammatory Factors
Therapeutic Apheresis and Dialysis, 2005Co-Authors: Midori Hasegawa, Asako Watanabe, Hiroki Takahashi, Kazuo Takahashi, Masami Kasugai, Nahoko Kawamura, Hiroko Kushimoto, Kazutaka Murakami, Makoto Tomita, Kunihiro NabeshimaAbstract:: To evaluate the efficacy of Cytapheresis for the treatment of rapidly progressive glomerulonephritis (RPGN) caused by myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA)-associated vasculitis, the renal prognosis and the mortality rate at 1 year after treatment were compared between a Cytapheresis Group and a Steroid Pulse Group. The Cytapheresis Group included 10 patients who were treated with Cytapheresis and oral corticosteroids. Five had granuloCytapheresis with the Adacolumn (Japan Immuno Research Laboratories Co. Ltd, Takasaki, Japan) and the remaining five had leukoCytapheresis with the leukocyte removal filter, Cellsorba (Asahi Medical Co. Ltd, Tokyo, Japan). The Steroid Pulse Group was comprised of 12 patients who were treated with methylprednisolone pulse therapy and oral corticosteroids. In the Cytapheresis Group, renal function recovered in 70% of the patients and the mortality rate was 10%. In the Steroid Pulse Group, renal function recovered in 66.7% and the mortality rate was 33.3%, with infection as the cause of death. Total doses of corticosteroids converted to prednisolone dose during a 1 month period, ranged from 280 mg to 1226 mg in the Cytapheresis Group. On the other hand, these dosages ranged from 2375 mg to 8380 mg in the Steroid Pulse Group. These results indicated that the mortality rate by infection could be reduced by adding Cytapheresis therapy. Concerning the mechanism of Cytapheresis, anti-inflammatory factors such as soluble tumor necrosis factor receptor, and interleukin-10 reduced after Cytapheresis. These changes might be responsible for the efficacy of Cytapheresis. In conclusion, Cytapheresis is thought to be one of the effective treatments for RPGN caused by MPO-ANCA-associated vasculitis, reducing the levels of anti-inflammatory factors.
Theodore A W Koerner - One of the best experts on this subject based on the ideXlab platform.
-
concurrent comparison of the safety of paid Cytapheresis and volunteer whole blood donors
Transfusion, 1994Co-Authors: Ronald G Strauss, G A Ludwig, M V Smith, P J Villhauer, M J Randels, A Smithfloss, Theodore A W KoernerAbstract:Background: Historically, paid blood donors were found to transmit hepatitis at higher rates than volunteers. In those older studies, paid donors frequently were recruited from prisons or slum areas–a finding consistent with the belief that monetary payment in itself did not necessarily lead to the high-risk status of commercial blood. Instead, it was the population base from which the donors were recruited that was important. Study Design and Methods: Today, Cytapheresis donors are in great demand. Because payment is one incentive that might entice donors to undertake the increased commitment of repeated Cytapheresis donation, the results were studied of infectious disease history and laboratory testing performed concurrently in 917 volunteer whole-blood donors and 1240 paid Cytapheresis donors, who were enrolled in distinct programs at the DeGowin Blood Center from October 7, 1987, through November 30, 1990. Results: When first, repeat, and overall donations made by these donors were evaluated separately, paid Cytapheresis donors were found to exhibit no increase in infectious disease history or test results beyond those of volunteer whole-blood donors. Conclusion: Thus, paid Cytapheresis donors, when managed within a formal program, should not necessarily be presumed to be more dangerous than volunteers, from an infectious disease aspect. However, definitive proof of safety (comparison of transfusion-transmitted infection rates in two groups of patients receiving blood components exclusively from either paid Cytapheresis or volunteer donors) was not pursued by long- term follow-up studies.
-
Concurrent comparison of the safety of paid Cytapheresis and volunteer whole‐blood donors
Transfusion, 1994Co-Authors: Ronald G Strauss, G A Ludwig, M V Smith, P J Villhauer, M J Randels, A. Smith-floss, Theodore A W KoernerAbstract:Background: Historically, paid blood donors were found to transmit hepatitis at higher rates than volunteers. In those older studies, paid donors frequently were recruited from prisons or slum areas–a finding consistent with the belief that monetary payment in itself did not necessarily lead to the high-risk status of commercial blood. Instead, it was the population base from which the donors were recruited that was important. Study Design and Methods: Today, Cytapheresis donors are in great demand. Because payment is one incentive that might entice donors to undertake the increased commitment of repeated Cytapheresis donation, the results were studied of infectious disease history and laboratory testing performed concurrently in 917 volunteer whole-blood donors and 1240 paid Cytapheresis donors, who were enrolled in distinct programs at the DeGowin Blood Center from October 7, 1987, through November 30, 1990. Results: When first, repeat, and overall donations made by these donors were evaluated separately, paid Cytapheresis donors were found to exhibit no increase in infectious disease history or test results beyond those of volunteer whole-blood donors. Conclusion: Thus, paid Cytapheresis donors, when managed within a formal program, should not necessarily be presumed to be more dangerous than volunteers, from an infectious disease aspect. However, definitive proof of safety (comparison of transfusion-transmitted infection rates in two groups of patients receiving blood components exclusively from either paid Cytapheresis or volunteer donors) was not pursued by long- term follow-up studies.
Ronald G Strauss - One of the best experts on this subject based on the ideXlab platform.
-
Effects on donors of repeated leukocyte losses during plateletpheresis
Journal of Clinical Apheresis, 1994Co-Authors: Ronald G StraussAbstract:All blood components collected by automated Cytapheresis contain donor leukocytes. The possibility that repeated Cytapheresis donation might lead to clinically important leukocyte losses and immunodeficiency has been a longstanding concern. Although convincing data do not exist to substantiate this concern, it is common practice to limit the number of annual Cytapheresis donations per donor and to monitor donors for developing lymphocytopenia. Clinically significant immunodeficiency is unlikely to occur unless donors lose >1 × 1011 lymphocytes within a few weeks period of time or unless donor lymphocyte counts fall persistently to
-
concurrent comparison of the safety of paid Cytapheresis and volunteer whole blood donors
Transfusion, 1994Co-Authors: Ronald G Strauss, G A Ludwig, M V Smith, P J Villhauer, M J Randels, A Smithfloss, Theodore A W KoernerAbstract:Background: Historically, paid blood donors were found to transmit hepatitis at higher rates than volunteers. In those older studies, paid donors frequently were recruited from prisons or slum areas–a finding consistent with the belief that monetary payment in itself did not necessarily lead to the high-risk status of commercial blood. Instead, it was the population base from which the donors were recruited that was important. Study Design and Methods: Today, Cytapheresis donors are in great demand. Because payment is one incentive that might entice donors to undertake the increased commitment of repeated Cytapheresis donation, the results were studied of infectious disease history and laboratory testing performed concurrently in 917 volunteer whole-blood donors and 1240 paid Cytapheresis donors, who were enrolled in distinct programs at the DeGowin Blood Center from October 7, 1987, through November 30, 1990. Results: When first, repeat, and overall donations made by these donors were evaluated separately, paid Cytapheresis donors were found to exhibit no increase in infectious disease history or test results beyond those of volunteer whole-blood donors. Conclusion: Thus, paid Cytapheresis donors, when managed within a formal program, should not necessarily be presumed to be more dangerous than volunteers, from an infectious disease aspect. However, definitive proof of safety (comparison of transfusion-transmitted infection rates in two groups of patients receiving blood components exclusively from either paid Cytapheresis or volunteer donors) was not pursued by long- term follow-up studies.
-
Concurrent comparison of the safety of paid Cytapheresis and volunteer whole‐blood donors
Transfusion, 1994Co-Authors: Ronald G Strauss, G A Ludwig, M V Smith, P J Villhauer, M J Randels, A. Smith-floss, Theodore A W KoernerAbstract:Background: Historically, paid blood donors were found to transmit hepatitis at higher rates than volunteers. In those older studies, paid donors frequently were recruited from prisons or slum areas–a finding consistent with the belief that monetary payment in itself did not necessarily lead to the high-risk status of commercial blood. Instead, it was the population base from which the donors were recruited that was important. Study Design and Methods: Today, Cytapheresis donors are in great demand. Because payment is one incentive that might entice donors to undertake the increased commitment of repeated Cytapheresis donation, the results were studied of infectious disease history and laboratory testing performed concurrently in 917 volunteer whole-blood donors and 1240 paid Cytapheresis donors, who were enrolled in distinct programs at the DeGowin Blood Center from October 7, 1987, through November 30, 1990. Results: When first, repeat, and overall donations made by these donors were evaluated separately, paid Cytapheresis donors were found to exhibit no increase in infectious disease history or test results beyond those of volunteer whole-blood donors. Conclusion: Thus, paid Cytapheresis donors, when managed within a formal program, should not necessarily be presumed to be more dangerous than volunteers, from an infectious disease aspect. However, definitive proof of safety (comparison of transfusion-transmitted infection rates in two groups of patients receiving blood components exclusively from either paid Cytapheresis or volunteer donors) was not pursued by long- term follow-up studies.
